Skip to main content
Study tests combo regimen in HCV genotypes 2, 4, 5, 6

The midstage, international C-SCAPE study, designed to assess the efficacy and safety of the combination drug elbasvir/grazoprevir with or without ribavirin in treatment-naive, noncirrhotic patients with hepatitis C virus genotypes 2, 4, 5 or 6, achieved its primary endpoint of sustained virological response after participants completed the 12-week regimen, according to a paper published in the Journal of Viral Hepatitis. The study was conducted in seven countries across 30 study sites.

Full Story: